Glycosylation determines essential biological functions of epithelial mucins in health and disease. We report on the influence of glycosylation of the immunodominant DTR motif of MUC1 on its antigenicity. Sets of novel glycopeptides were synthesized that enabled us to examine sole and combined effects of peptide length (number of repeats) and O-glycosylation with GalNAc at the DTR motif on the binding patterns of 22 monoclonal antibodies recognizing this motif. In case of unglycosylated peptides almost all antibodies bound better to multiple MUC1 tandem repeats. Glycosylation at the DTR led to enhanced binding in 11 cases, whereas 10 antibodies were not influenced in binding, and one was inhibited. In nine of the former cases both length and DTR glycosylation were additive in their influence on antibody binding, suggesting that both effects are different. Improved binding to the glycosylated DTR motif was exclusively found with antibodies generated against tumor-derived MUC1. Based on these data a tumor-specific MUC1 epitope is defined comprising the ...PDTRP... sequence in a particular conformation essentially determined by O-glycosylation at its threonine with either GalNAca1 or a related short glycan. The results can find application in the field of MUC1-based immunotherapy.
Introduction
MUC1 is a highly O-glycosylated transmembrane glycoprotein (mucin) typically but not exclusively expressed on glandular epithelia and on epithelial tumors. It is an established serum tumor marker, especially in breast cancer patients (Hayes et al., 1986; Safi et al., 1991) , and has in recent years attracted increasing attention as a potential target of tumor immunotherapies (Taylor-Papadimitriou et al., 1999; Finn et al., 1995) . Whereas the case for the former is clear-cut, the rationale for the latter is not, especially with respect to the selection criteria for antibodies suitable as targeting vehicles and the design of efficient vaccines.
In the mid-1990s a plethora of monoclonal anti-MUC1 antibodies became available that required comparison and standardization. Thus the ISOBM TD-4 International Workshop on Monoclonal Antibodies against MUC1 in 1996 became a landmark in the field. Fifty-six supposedly MUC1-specific monoclonal antibodies (mAbs) were compared and their epitopes mapped .
At that time it was well established that tumor MUC1Ð similar to other membrane glycoproteinsÐdiffers from normal MUC1 by modified (essentially truncated) glycan side chains, which results in a better accessibility of peptide epitopes (Brockhausen, 1999; Burchell et al., 2001; Lloyd et al., 1996; Taylor-Papadimitriou et al., 1999) . In addition, it was assumed that the immunodominant DTR motif was generally not glycosylated . Thus the tumor specificity of anti-MUC1 mabs was interpreted solely in terms of better access to peptide epitopes due to reduced interference by glycans located in the vicinity of the epitope. This picture changed when we found that the DTR sequence is actually glycosylated (M uller et al., 1997) and that short glycans typical for tumor MUC1 (GalNAca1-or Galb1-3GalNAca1-) at this site may even improve antibody binding to the DTR epitope . Our hypothesis was that glycosylation at this site might induce a knoblike structure similar to that described for repetitive non-glycosylated tandem repeat peptides (Fontenot et al., 1995) . Employing a large panel of monoclonal anti-MUC1 antibodies and three sets of specially devised antigenic structures, among them a unique set of novel synthetic glycopeptides, we continued our studies with the aim of a more refined epitope characterization. As a result, we were able to (1) dissect the glycosylation effect from the length effect, (2) describe subgroups of anti-MUC1 antibodies recognizing the DTR motif, and (3) define a novel tumor-specific MUC1 epitope.
Results

Length dependency
We first reexamined the binding patterns of the antibody panel listed in Table I toward nonglycosylated MUC1 peptides of increased length (oligomerization of 20-amino-acidlong tandem repeats). For this purpose, we determined the absorbance (A) increment of antibody binding occurring during prolongation from one up to six tandem repeat lengths. For the purpose of data reduction we included in Table II only the absorbance ratios A 100-mer :A 20-mer , and classified these values into groups of length dependency as follows. LD-1: absolutely dependent (A of the 20-mer 5 0.1 irrespective of their A 100 :A 20 ratio); LD-2: strongly dependent (ratio 4 3.0); LD-3: weakly influenced (ratio 1.5±2.9); LI: independent (ratio 5 1.5). Almost all antibodies showed increased binding toward the longer peptides, but this increase differed considerably among individual antibodies. A subgroup was almost nonreactive with the single repeat but revealed significant and increasing binding with increased numbers of repeats.
Two control antibodies recognizing non-DTR epitopes (BCP9, MF11) were found weakly influenced by peptide length (LD-3) in their binding. MF11 was not binding to the 20-mer, obviously because its epitope was too close to the end of the peptide.
Glycosylation dependency
The unexpected observation made by us in 1997 that many antibodies specific for the immunodominant DTR region of MUC1 bound better to the glycosylated than to the unglycosylated epitope was reexamined in this study with a specially devised 30-mer peptide/ glycopeptide pair of test antigens with the DTR motif situated in the middle of the peptide, and its threonine O-glycosylated with GalNAca in the glycopeptide variant. Absorbance ratios A glycosylated :A unglycosylated were calculated for each antibody and are presented in Table II . These ratios were taken from one experiment but confirmed in repeated experiments of the same kind and also in different experiments employing the same but N-terminally biotinylated peptide and glycopeptide, respectively. No qualitative differences were observed between direct coating to the polystyrene surface and coating via biotin/streptavidin, confirming that the glycosylation effect was not due to a different degree of binding of glycopeptides as compared to their unglycosylated counterparts on the solid phase. Differences in absorbance seen between individual experiments did not change in any case the classification of the antibodies, which was done as follows. GD-1: binding strongly dependent on DTR glycosylation (ratio 4 6); (Burchell et al., 1987) .
GD-2: moderately influenced (ratio 1.3±5.9); GI: independent of glycosylation (ratio 0.8±1.2); iGD: inversely influenced (binding inhibited) by glycosylation (ratio 5 0.8).
The results showed that about half of the antibodies were glycosylation-influenced, that is, revealed better binding to the glycosylated epitope. Only in one case (VU-4H5) was inhibition of antibody binding observed after glycosylation of the epitope with GalNAc.
Both control antibodies recognizing non-DTR epitopes (BCP9, MF11) were found not influenced by DTR glycosylation in their binding, as could have been anticipated.
Combined glycosylation and length effects
Both the length effect and the glycosylation effect suggest a modification of the conformation of the DTR region as the reason for improved antibody binding, which for the length effect has indeed been demonstrated (Fontenot et al., 1993) . Therefore, we were interested to examine whether increasing peptide length and glycosylation at the DTR lead to the same assumed conformation as indicated by an identical maximum absorbance or whether both effects are additive and can be distinguished. This question could be resolved with a novel series of glycopeptides (O-glycosylated with GalNAc at the threonine of each DTR motif) of different length (one to five tandem repeats); see Table III .
The results demonstrate that the length effect and the effect of DTR glycosylation on antibody binding can be clearly distinguished. Figure 1 presents examples of binding patterns in response to oligomerization of MUC1 glycopeptides found among glycosylation-dependent antibodies. As can be seen, the increment in absorbance varies from strong to weak, and there are also cases where no additional length effect can be observed ( Figure 1D ). The frequencies of these four types of reactivity can be taken from Table IV (last column). Nine out of the 11 antibodies of this group revealed an additive influence of glycosylation and length, clearly indicating that both effects are different.
Antibodies not influenced by DTR glycosylation reproduce in most cases with glycosylated peptides the length dependency patterns seen with naked peptides. An effect of increased length was seen in 4 out of 11 cases (Table V) , with only one mAb (HMFG-1) showing strong influence (see Figure 4 , later). An exception was mAb Mc5, which revealed different binding patterns to glycosylated versus unglycosylated peptides with respect to length dependency. This case also provides evidence that the length effect is not an artifact of coating (e.g., due to an improved polystyrene binding of longer glycopeptides); the same conclusion can be drawn from the length-independent binding of mAb C595 with naked peptides. Weakly length-influenced mAbs (LD-3) did not show any length increment with oligomeric glycosylated peptides ( Figure 2A±C ). An interesting case is mAb VU-4H5 ( Figure 2D ), which was inhibited by DTR glycosylation but clearly responded to increased peptide length.
Binding patterns of the two antibodies selected as internal controls are shown in Table VI and Figure 3 . As expected, their binding was independent of glycosylation, and the influence of peptide length, if any, was marginal. In case of mAb MF11 ( Figure 3B ), the epitope was obviously not sufficiently exposed in the 20-mer.
Periodate oxidation
Periodate treatment according to Woodward et al. (1985) is a valuable tool to confirm carbohydrate involvement in immunological recognition. This treatment cleaves sugar rings between vicinal OH groups and renders the structure unrecognizable for a specific antibody. It was therefore of interest to examine to what extent the observed effects were Absorbance ratio A 100-mer :A 20-mer . b LD-1: absolutely dependent (A of the 20-mer 5 0.1 irrespective of their A 100 :A 20 ratio); LD-2: strongly dependent (ratio 4 3.0); LD-3: weakly dependent (ratio 1.5±2.9); LI: independent (ratio 5 1.5). These data were obtained with compounds of series I (see Materials and methods). c Absorbance ratio A glycosylated :A unglycosylated peptide . d GD-1: strongly dependent (ratio 4 6); GD-2: moderately dependent (ratio 1.3±5.9); GI: independent (ratio 0.8±1.2); iGD: inversely influenced (binding inhibited, ratio 5 0.8). These data were obtained with compounds of series II (see Materials and methods). e This quotient is invalid due to the zero reactivity with the 20-mer (the epitope of this mAb is too close to the end of the 20-mer; compare Table VI and Figure 3B ). f Classified as LD-3 due to a slight A increment from the 60-mer to the 120-mer.
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actually carbohydrate-induced, and if so, whether they were reversible. The results shown in Figure 4 confirmed that the binding of mAb A76-A/C7 is glycosylation-conditioned ( Figure 4A ). However, the length effect partially compensates for the decrease in binding caused by periodate oxidation. This confirms the conclusion that both effects may overlap but are not identical. A different binding pattern was provided by mAb HMFG-1, whose binding is strongly influenced by the number of tandem repeats but not by DTR glycosylation ( Figure 4B ). An antibody classified as being neither glycosylation-nor length-dependent, E29, revealed a binding pattern as expected in this case and was not influenced by periodate oxidation of the glycopeptide in its binding ( Figure 4C ). This is also proof that the peptide was not damaged under these conditions. Interestingly, binding of antibody VU-4H5, which is suppressed by DTR glycosylation, was not restored after periodate oxidation but increased moderately with increased peptide length ( Figure 4D ). The unique behavior of mAb VU-4H5 suggests steric hindrance of antibody binding by the glycan even after oxidative ring cleavage and again demonstrates the length effect as an independent phenomenon.
Search for possible correlations
The fact that about half of the antibodies bound better to the glycosylated epitope initiated a search for possible correlations to other known properties of the antibodies, such as length dependency, isotype, epitope characteristics, immunogen, or the efficiency to detect carcinoma-specific MUC1. Except length and DTR-glycosylation influence, which were based on our own data (Table II) , the other parameters were taken from the reports of the 1996 workshop . In detail, isotypes, peptide Fig. 1 . Binding patterns of antibodies generated against tumor MUC1 to an unglycosylated VNTR peptide (first column) and to glycosylated VNTR peptides of different length (one to five repeats). All bind better to DTR-glycosylated peptides. A subgroup reveals an additional binding increment with increasing number of repeats (A strong, B moderate, C weak).
U. Karsten et al. Taken from Norum et al. (1998, A second binding site has been recently described (Grinstead et al., 2002) .
f Partially deglycosylated human milk fat globule membranes (Burchell et al., 1987) , see Results.
Antibody binding patterns to MUC1 Taken from Norum et al. (1998, sequences agreed on as epitopes and immunogens were taken from the Summary Report , whereas the efficiency data were from Table 3 in Norum et al. (1998) . The latter were arbitrary points based on the efficiency with which solid phase-coated antibodies presented shed tumor MUC1 (from a pool of patients' sera) for a given tracer antibody in immunoradiometric sandwich assays. Among the examined parameters, the strongest correlation was found between glycosylation dependency and the type of immunogen used for generating the antibody (Tables IV and V) . In fact, among the antibodies included in the study, all mAbs generated with immunogens from human tumor sources (e.g., breast cancer cells or MUC1 prepared from tumor ascites) bound better to the DTRglycosylated peptide than to the naked peptide. The extent of this phenomenon varied from strong to weak. On the other hand, almost all mAbs generated with immunogens from nontumor sources (e.g., naked peptides or milk fat globule membranes) were glycosylation-independent. The only exception was SM3, which was generated with partially deglycosylated HMFG as immunogen, and was slightly glycosylation-influenced. It should be mentioned, however, that this preparation was treated with anhydrous hydrogen fluoride (Burchell et al., 1987) , which, under mild 
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conditions (1 h at 0 C), leaves GalNAc O-glycosidically bound to the peptide backbone intact (Mort and Lamport, 1977) , resulting in structures similar to the tumor epitope defined by us (see Discussion).
Among the other parameters, some interesting correlations to the two subgroups (glycosylation-dependent [A, Table IV ] versus glycosylation-independent mabs [B, Table V ]) were also found. First, the length dependency is more pronounced in subgroup A compared to B. Second, in subgroup A the mean peptide length of the epitopes (8.4 amino acids) was longer than in subgroup B (5.6 amino acids). Both differences may be interpreted as indicators of the prevalence of conformation epitopes rather than sequence epitopes in glycosylation-effected MUC1 antibodies. Efficiency points in recognizing shed tumor MUC1 according to Norum et al. (1998) were also differing U. Karsten et al. between groups A and B. The numerical sum of all points of group A was 435 as compared to 218 in group B, although individual scores varied considerably. This can be explained by the fact that shed tumor MUC1 is obviously different from cell-bound tumor MUC1 because it is only weakly detected by some mAbs (unpublished data). No correlation was found to isotypes.
Discussion
In continuing earlier studies on the influence of glycosylation on the binding of antibodies to peptide epitopes of MUC1 (Cao et al., 1997a (Cao et al., ,b, 1998 Cao and Karsten, 2001; Karsten et al., 1998) , we reexamined, with a large panel of 22 mAbs to the immunodominant DTR motif of MUC1, their binding patterns with respect to peptide length (i.e., the number of tandem repeats) and DTR glycosylation. Essential results were that the impacts of length and glycosylation on antibody binding, which at first hand appeared to be similar, were in fact different (and in a subgroup of mAbs additive), and that the presence or absence of the glycosylation effect split the antibody population into two groups. The most astonishing result was that antibodies generated from tumor-derived MUC1 were all glycosylationinfluenced, whereas those generated from nontumor MUC1 were independent of DTR glycosylation in their binding behavior. We interpret this as clear evidence that tumor MUC1 contains a tumor-specific conformation epitope of the structure: ...PDT*RP..., where T* is O-glycosylated with GalNAca1-or a similar short, nonsialylated glycan, such as Galb1-3GalNAca1 (core 1).
Our conclusion is supported by a recent study in which the fine specificities of anti-MUC1 antibodies in human sera were reported. Anti-MUC1 antibodies from breast cancer patients revealed a preference for glycosylated peptides (Von Mensdorff-Pouilly et al., 2000a).
The present study was done with GalNAca1-substituted peptides; from our earlier data it can be inferred that Galb1-3GalNAca1-instead of GalNAca1-is equally effective with respect to an enhanced binding of antibodies of the respective group. Both are typical glycans of tumor MUC1 (Goletz et al., 2003; Lloyd et al., 1996) . However the glycan moiety itself is not directly recognized by the MUC1 antibodies. This can be inferred from the following: (1) all mAbs included in this study recognize defined peptide sequences and bind significantly to unglycosylated oligomeric MUC1 tandem repeats; (2) binding increments by glycosylation are similar with either GalNAca1-or Galb1-3GalNAca1-, which are two immunologically completely different entities; (3) the mAbs do not bind to either of the glycans in enzyme-linked immunosorbent assay (ELISA) (data not shown); and (4) structural studies with mAb SM3 (glycosylation-dependent, Table II ) revealed no evidence for carbohydrate involvement in binding (M oller et al., 2002) .
A number of nuclear magnetic resonance (NMR) studies have dealt with the secondary structure of the DTR motif (Fontenot et al., 1993 (Fontenot et al., , 1995 Grinstead et al., 2002; Kirnarsky et al., 2000; Scanlon et al., 1992; Schuman et al., 2003; Tendler, 1990) . In one case, the crystal structure of an antibody-peptide complex has been accomplished (Dokurno et al., 1998) . The influence of peptide elongation (from one to three nonglycosylated tandem repeats) was described as leading to a knoblike, type I b-turn conformation of the region around DTR (Fontenot et al., 1993 (Fontenot et al., , 1995 . The effect of DTR glycosylation on its conformation has recently been investigated (Kirnarsky et al., 2000; M oller et al., 2002) , albeit only with short glycopeptides. Attachment of GalNAca1-O-shifts the conformation of the DTR motif from the type I b-turn toward a more rigid and extended state (Schuman et al., 2003) . This supports our suggestion that length and glycosylation effects lead to different conformations of this region.
O-glycosylation with GalNAc has also been shown to result in a more rigid conformation in case of peptides other than MUC1 (Huang et al., 1997; Live et al., 1999) .
Whereas a b-turn within the DTR motif may explain the immunodominance of this region in case of the unglycosylated peptide (Fontenot et al., 1993 (Fontenot et al., , 1995 Schuman et al., 2003) , our data suggest that this is not the tumor-specific MUC1 epitope. The correlations found by us imply that tumor MUC1 contains the glycosylated DTR, which is in agreement with biochemical data (M uller et al., 1999) , and indicate the prevalence of conformation epitopes rather than sequence epitopes among DTR-specific antibodies generated against tumor MUC1. We hypothesize that the tumor-specific MUC1 epitope is a certain conformation of the ...PDTRP... epitope. Its exact structure, of course, cannot be deduced from our data. It should have similarity to that described by Schuman et al. (2003) , but may be modified by the length effect. In any case, the tumor-specific MUC1 epitope is clearly different from what it hitherto was believed to be. The oligomeric MUC1 glycopeptides described here could provide an excellent subject for structural studies, which may be able to elucidate the complex interplay of glycosylation and oligomerization on the conformation of this immunologically important site of tumor MUC1.
Our results should be relevant to MUC1-based immunotherapies. Antibodies that specifically recognize the epitope described here are less prone to bind to normal MUC1. This explains, at least in part, the already described more or less tumor-specific histological staining pattern of some MUC1 antibodies, for example, SM3 (Burchell et al., 1987) or A76-A/C7 (Cao et al., 1997a) . However, it is evident from this and earlier studies (Cao and Karsten, 2001; Norum et al., 1998) that even nominally similar antibodies reveal astonishing differences in their fine specificity. In addition, the selection of an individual antibody for adjuvant immunotherapy depends on a number of other parameters, too. The case for cancer vaccines is more straightforward. On the one hand, the DTR motif is well known as a B cell epitope. The presence of anti-MUC1 antibodies in the serum has been found beneficial for breast cancer patients (Von MensdorffPouilly et al., 2000b) . On the other hand, among known MUC1 T cell epitopes (Brossart et al., 1999; Feuerer et al., 2001) , the DTR region has also been reported (Gad et al., 2003; Mukherjee et al., 2000) . Most recently, Apostolopoulos et al. (2003) have actually shown that glycosylation with GalNAc at the DTR motif leads to a high-affinity binding to a murine major histocompatibility Antibody binding patterns to MUC1
class I molecule, H-2Kb, and that the glycosylated MUC1 peptide is able to evoke strong specific T cell responses in vitro and in vivo. Similar results have been obtained with other proteins (e.g., a lysozyme peptide; Harding et al., 1993) . In conclusion, we propose that MUC1-based cancer vaccines should contain the ...PDTRP... sequence O-glycosylated at the threonine with Tn or TF (i.e., in a conformation corresponding to tumour MUC1).
Materials and methods
Antibodies
Twenty-two mAbs toward the immunodominant DTR motif of MUC1 were selected from the TD-4 Workshop panel for this study. In addition, two MUC1 mAbs with epitopes distant from this motif were included. The antibodies selected, their isotypes, and the immunogens employed for their generation (taken from Rye and Price, 1998) are listed in Table I together with their nominal epitope sequences as determined by the TD-4 Workshop .
Peptides and glycopeptides
Three sets of synthetic peptides/glycopeptides, all based on the MUC1 tandem repeat sequence, were employed for three different series of experiments.
Series I. Unglycosylated 20-mers and their oligomers of the type [VTSAPDTRPAPGSTAPPAHG] n , with n 1, 3, 4, 5, and 6, were obtained from Dr. J. Hilgers (Department of Obstetrics and Gynaecology, Free University, Amsterdam, The Netherlands). In the peptides with n 3±6, R was missing in the second repeat.
Series II. A glycosylated 30-mer with the sequence APPA-HGVTSAPDT[GalNAca]RPAPGSTAPPAHGVTSA and its unglycosylated counterpart were synthesized by Biosyntan GmbH (Berlin-Buch). In addition, the same pair of glycosylated versus unglycosylated peptide was prepared in an N-terminally biotinylated form, which then could be coated more quantitatively on streptavidin microtiter plates (see later description). Biotinylation (with 6-aminohexanoic acid as N-terminal spacer) was performed as follows. Biotin was preactivated with 2-(1H-benzotriazole-1-yl)-1,1,3, 3-tetramethyluronium tetrafluoroborate and N-methylmorpholine in N-methylpyrrolidone for 10 min, and this mixture together with the solid phase containing the peptide/glycopeptide was stirred for 2 h. Series III. A novel series of glycosylated MUC1 tandem repeat peptides of different length of the sequence A[HGV-TSAPDT(GalNAca)RPAPGSTAPPA] n , with n 1±5 (TR1a±TR5a), was synthesized (Table III) .
The synthesis of the glycopeptides was conducted as a glycopeptide solid phase synthesis on Wang resin via the 9-fluorenyl-methoxycarbonyl (FMOC) 3 technique. The amino acids were coupled as FMOC-fluorophenylesters, and the FMOC-ThrGalNAc building blocks with the help of O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate. The synthesis was started with a larger amount of resin (2.5 g) until TR1a was reached. One-fifth of the resin was then removed, and the synthesis was continued with the remaining resin via TR2a, TR3a, TR4a, and TR5a. After each of the intermediates had been achieved, a portion of the resin was removed, and the majority of the resin was used for the next step. The deacetylation of the saccharide was conducted with methanol/hydrazine 5:1 except for TR4a and TR5a, where 2-propanol/hydrazine 5:1 was used. Cleavage from the resin was achieved with 0.1% aqueous trifluoroacetic acid (95%). The purification of the substances was carried out by high-pressure liquid chromatography on reversed phase columns (RP18) in a gradient mode with water/acetonitrile as mobile phase.
Structural elucidation was performed with NMR spectroscopy, and the molecular weights were determined by matrix-assisted laser desorption and ionization mass spectrometry.
Enzyme immunoassays
ELISAs were performed as follows.
Experimental series I (length effect). Polystyrene microtiter plates of tissue culture type (Nunc, Wiesbaden, Germany) were coated with 50 ml per well of a solution of 10 mg/ml of peptide (from series I) in 0.1 M carbonate buffer, pH 9.6, overnight at 37 C to dryness. Antigens to be compared were always coated on the same plate. After three washes with phosphate buffered saline (PBS)/ 0.05% Tween 20, the purified antibodies were added (50 ml, 10 mg/ml) in PBS/Tween containing 1% bovine serum albumin (BSA), and incubated for 2 h in a moist chamber at 37 C. After three washings as before, the plates were incubated with peroxidase-labeled rabbit anti-mouse immunoglobulin serum (P260, Dako, Hamburg, Germany) diluted 1:2000 in PBS/BSA for 1.5 h at 37 C. After three final washings, color development was accomplished with o-phenylenediamine, and the absorbance (A) measured with a Spectra plate reader (SLT Labinstruments, Salzburg, Austria) at 492 nm. Blank values were subtracted, and means were calculated. From the means, ratio values A 100-mer :A 20-mer were calculated.
Experimental series II (glycosylation effect). Experimental details were similar to series I except that the 30-mer peptide and glycopeptide from series II were employed, and water was used for coating instead of carbonate buffer to avoid belimination during the drying process. To exclude the possibility that glycopeptides and peptides sticked differently to the plastic, a parallel series of experiments with biotinylated (glyco)peptides was performed. In this case, the protocol was modified as follows. Streptavidin-precoated microtiter plates (BioTeZ, Berlin-Buch) were coated with 100 ml per well containing 0.5 mg/ml of the biotinylated antigen in PBS/BSA (1 h at room temperature). The following steps were as described except that 100 ml volumes were used throughout and the concentrations of the primary and second antibodies were halved. Blank values were subtracted, and means were calculated. From the means, ratio values A glycosylated peptide :A unglycosylated peptide were calculated.
U. Karsten et al. Experimental series III (combined effects). Experimental details were similar to series I except that glycopeptides of series III were employed and water was used for coating instead of carbonate buffer. The concentration of the primary antibodies was varied between 0.1 and 5 mg/ml. Evaluation of binding patterns was generally based on data obtained at 5 mg/ml, although in most cases the overall patterns were found consistent for a given mAb within the whole concentration range. In some experiments the antigen concentration was also varied. Best results were obtained at 10 mg/ml. In some experiments, 3,3 H ,5,5 H -tetramethylbenzidine instead of o-phenylenediamine was used as substrate for peroxidase, and A was measured at 450 nm.
In all ELISA experiments, coating was done on a weight per ml basis to approximate equimolar concentrations of tandem repeats.
In some cases, carbohydrate-selective periodate oxidation of the coated antigens (10 mM NaIO 4 in 50 mM sodium acetate buffer, pH 4.5, for 1 h at 25 C, followed by reduction of aldehydes by 50 mM NaBH 4 ) was performed as described (Woodward et al., 1985) .
Values were generated in duplicates and repeated at least three times. Graphs were prepared with the GraphPad Prism 3.0 program (GraphPad Software, San Diego, CA). Error bars indicate SE.
